Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Legislative Reform: Pan-EU Launch Requirement Will ‘Take Two To Tango’

Executive Summary

Companies are already used to uncertainty and will be able to adapt to the new product launch requirement in the EU’s legislative overhaul for the pharmaceutical sector, according to a commission representative.

You may also be interested in...



EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives

The EU’s regulatory reform package if unchanged could make orphan drug development less attractive, warn industry representatives.

UK Government Reveals New Statutory Pricing Scheme

The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.

Premature Filings Add To EU Regulatory Resource Challenge

The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel